VS-7375 -(TARGET-D 202)

July 22, 2026: Verastem Oncology (NASDAQ: VSTM) announced first patient dosed in TARGET-D 202 (NCT07659782), a global open-label Phase 2, registration-directed trial of VS-7375 (investigational oral KRAS G12D ON/OFF inhibitor) monotherapy at the RP2D of 900 mg QD in previously treated KRAS G12D-mutated advanced NSCLC. Eligible patients have unresectable locally advanced/metastatic disease that progressed after platinum-based chemotherapy and anti–PD-(1) therapy; a cohort will evaluate patients with asymptomatic untreated brain metastases. The trial is intended to support a potential registration strategy.

Program context and upcoming catalysts: Verastem initiated the Phase 1/2 TARGET-D 101 in June 2025 across KRAS G12D-mutant mPDAC, mCRC, NSCLC and other solid tumors; the company previously reported “encouraging” activity and expects a further update in 2H 2026. Three registration-directed Phase 2 trials are part of the program: TARGET-D 201 (PDAC; first patient dosed announced June 2026), TARGET-D 202 (NSCLC; this update), and TARGET-D 203 (mCRC; first-patient dosing planned next). FDA granted Fast Track designation to VS-7375 in July 2025 (pancreatic indications listed) and in June 2026 (previously treated KRAS G12D-mutant advanced NSCLC).